List view / Grid view

Sharon Benzeno (Adaptive Biotechnologies)

 

article

Neoantigen-directed cancer treatment

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer,…

9 June 2023 | By

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

article

Neoantigens: presenting new vaccine opportunities in immuno-oncology

Neoantigens have gained much interest in recent years, mainly due…

4 June 2020 | By

Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.